MRD test to predict therapy success in advanced prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This study tests if a blood test for 'minimal residual disease' (tiny bits of cancer left after treatment) can help predict how well therapy works for prostate cancer that has spread and is sensitive to hormones. It aims to find better ways to guide treatment and monitor the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 85 years old.
- Your prostate cancer is a specific type (acinar, ductal, or intraductal) and has spread to other parts of your body.
- You have not had hormone therapy or other cancer treatments for this condition before.
- You are generally in good health (able to do daily activities) and expected to live more than 6 months.
- Your blood and organ function tests meet certain levels (your doctor can check this).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new way to find microscopic cancer cells (minimal residual disease) in the blood after prostate surgery. If successful, it could help doctors decide if additional treatment is needed.
This study checks whether certain blood markers can help predict how well people with prostate cancer will respond to therapy. It may help doctors choose the most effective treatment sooner by using information from your blood.
This study tests whether adding a type of high-precision radiation (MDRT) to standard hormone therapy works better for men with prostate cancer that has spread to just a few places. It is for patients who are newly diagnosed and on long-term hormone therapy.
This study is looking at a test called MRD (minimal residual disease) to see if it can guide decisions about local treatments (like surgery or radiation) for people with breast cancer that has spread to a few spots. It may help doctors know when to use these treatments and when to wait.
This study looks at men with aggressive, high-volume metastatic prostate cancer that is still sensitive to hormone therapy. It will analyze a blood test for HRR gene mutations (like BRCA) to help understand treatment patterns.
This trial studies a blood test that looks for tumor DNA in men with high-risk or advanced prostate cancer. It may help doctors understand the cancer better and guide treatment decisions.
Hear when a new MRD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.